Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Active, not recruiting · Phase 1, Phase 2 · NCT05471843
Conditions: Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma
At a glance
- Research payments reported, 2025
- $307,142
- U.S. investigators named
- 11
- Sites paid
- 12
- Planned or actual enrollment
- 125
About the trial
- Sponsor
- BeOne Medicines
- Tested
- Sonrotoclax (drug)
- Dates
- Started 2022-09-05; completion 2027-01-31
- Results posted
- Yes
The study consists of two parts. Part 1 determines the safety and tolerability of sonrotoclax monotherapy, the maximum tolerated dose, and the recommended Phase 2 dose of sonrotoclax monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of sonrotoclax monotherapy at the recommended Phase 2 dose with recommended ramp-up schedule from Part 1.
From ClinicalTrials.gov, last updated 2026-09-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beigene, Ltd. reported $307,142 in research payments for this study in 2025 (46 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Mayur Narkhede, M.D. Medical Oncology · Birmingham, AL
- Ira Smalberg, MD Radiology · Santa Monica, CA
- Imad A. Tabbara, M.D. Hematology & Oncology · Washington, DC
- George R. Oliveira, M.D. Interventional Radiology · Miami, FL
- David Morrison, MD Hematology & Oncology · New Orleans, LA
- Alan P. Zausner Skarbnik, MD Hematology · Charlotte, NC
- Frederick Lansigan, M.D. Hematology & Oncology · Lebanon, NH
- Andrew C. Ip, M.D. Medical Oncology · Hackensack, NJ
- Adelba Torres-lopez, M.D. Hematology & Oncology · San Juan, PR
- Luhua M. Wang, M.D. Hematology & Oncology · Houston, TX
- Mohammed N. Kanaan Hematology & Oncology · Puyallup, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Alabama Hospital, AL $157,880
- Tulane Cancer Center $67,752
- Ggs Diagnostics LLC $22,970
- $13,450
- Ut MD Anderson Cancer Center $9,119
- Dartmouth Cancer Center $8,580
- Radmetrix $6,600
- Novant Health Hematology - Charlotte $6,366
- Novant Health Clinical Research $3,650
- Hackensack University Medical Center, NJ $3,360
- Auxilio Mutuo Hospital, PR $2,750
- Luminis Health Anne Arundel Medical Center $2,500
- Northwest Medical Specialties, PLLC $2,165
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.